Biosensors has announced that it has launched a larger version of its Axxess bifurcation drug-eluting stent. The new 4.0x9mm size received the CE mark in September and has been specifically designed for the safe and effective treatment of bifurcation lesions involving large main branch vessels and wide bifurcation angulation. The stent was launched at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium (27 October–1 November, San Francisco, USA).
According to a press release, Axxess 4.0×9 features a self-expanding nitinol (nickel/titanium) stent platform, to accommodate the anatomical diameter mismatch between the proximal large main branch vessel and bifurcation. Its distal flared end has been specifically designed to protect a higher vessel angulation. As with the existing stents in the Axxess range, Axxess 4.0×9 is abluminally coated with a biodegradable poly-lactic acid polymer that releases Biolimus A9 (BA9).
“With the addition of Axxess 4.0×9 to our current Axxess portfolio, a broader range of bifurcation lesions will benefit from our specialized technology. The Axxess line offers the unique benefits of a dedicated self-expanding bifurcation stent,” commented Jeffrey B Jump, president of Biosensors’ Cardiovascular Division.
